Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Infectious Disease Diagnostics Market by Product (Reagents, Assays, Instrument), Test (Laboratory, POC), Technology (Immunodiagnostics, Microbiology, PCR, NGS, INAAT), Disease (COVID-19, Hepatitis, HAI, HIV, Influenza), End User-Global Forecast to 2026

Published by MarketsandMarkets Product code 1008510
Published Content info 257 Pages
Delivery time: 1-2 business days
Price
Back to Top
Infectious Disease Diagnostics Market by Product (Reagents, Assays, Instrument), Test (Laboratory, POC), Technology (Immunodiagnostics, Microbiology, PCR, NGS, INAAT), Disease (COVID-19, Hepatitis, HAI, HIV, Influenza), End User-Global Forecast to 2026
Published: May 26, 2021 Content info: 257 Pages
Description

The global infectious disease diagnostics market size is projected to reach USD 39.8billion by 2026 from USD 28.1billion in 2021, at a CAGR of 7.2% during the forecast period. Market growth is driven by factors such as global prevalence of infectious diseases & onset of COVID-19 and the growing awareness for early disease diagnosis, shift in focus from centralized laboratories to decentralized POC testing and rising technological advancements. On the other hand, an unfavorable reimbursement scenario is expected to limit market growth to a certain extent in the coming years.

"The reagents, kits, and consumablesaccounted for the highest growth rate in theinfectious disease diagnostics market, byproduct& service, during the forecast period"

The infectious disease diagnostics market is segmented into reagents, kits, and consumables; instruments; and software & services. The reagents, kits, and consumables segment accounted for the highest growth rate in the infectious disease diagnostics market in 2020. The requirement of reagents, kits and consumables in large numbers compared to instrumentsis the main factor contributing to this segment's high growth rate. This segment's market growth can also be attributed to repeat purchases of reagents, kits, and consumables compared to instruments.

"HAIs segment accounted for the highest CAGR"

Based on the disease type, the infectious disease diagnostics market is segmented into COVID-19, HIV, HAIs, hepatitis, CT/NG, HPV, TB, influenza, and other infectious diseases. The increasing number of cases and the availability of many COVID-19 diagnostic tests are driving the growth of this market. In 2020, the HAIs segment accounted for the highest CAGR.

"Diagnostic Laboratoriessegment accounted for the highest CAGR"

Based on end-users, the infectious disease diagnostics market is segmented into diagnostic laboratories, hospitals & clinics, academic research institutes, and other end users. In 2020, the diagnostic laboratories segment accounted for the highest CAGR. This can be attributed to increased test volume of infectious diseases and strengthening healthcare infrastructure for efficient disease diagnosis and treatment.

"Asia Pacific: The fastest-growing regioninfectious disease diagnostics market"

The global infectious disease diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Factors such as government efforts to increase awareness about the early detection of diseases and regular health check-ups, continuously rising healthcare expenditure, increasing number of hospitals, clinical diagnostic laboratories in India and China, and strengthening research base for diagnostic procedures across India, China, and Japan are driving the growth of the infectious disease diagnosticsmarket in this region.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 - 20%, Tier 2 - 45%,and Tier 3 -35%
  • By Designation: C-level - 30%, D-level - 20%, and Others - 50%
  • By Region: North America -36%, Europe - 25%, Asia Pacific - 27%, Latin America - 9%, and the Middle East & Africa - 3%

Lits of Companies Profiled in the Report:

  • Abbott Laboratories (US)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • bioMerieux SA (France)
  • Thermo Fisher Scientific Inc. (US)
  • Danaher Corporation (US)
  • QuidelCorporation(US)
  • Hologic, Inc. (US)
  • PerkinElmer Inc. (US)
  • Bio-Rad Laboratories, Inc. (US)
  • QIAGEN (Netherlands)
  • Siemens Healthineers AG (Germany)
  • Becton, Dickinson and Company (US)
  • DiaSorin S.p.A (Italy)
  • Grifols S.A. (Spain)
  • Sysmex Corporation (Japan)
  • Ortho Clinical Diagnostics (US)
  • Genetic Signatures (Australia)
  • Luminex Corporation (US)
  • Meridian Bioscience (US)
  • OraSure Technologies (US)
  • Trinity Biotech Plc. (Ireland)
  • Chembio Diagnostic Systems, Inc. (US)
  • Seegene Inc. (South Korea)
  • Co-Diagnostics, Inc. (US)
  • ELITechGroup (France)
  • Epitope Diagnostics, Inc. (US)
  • Trivitron Healthcare (India)
  • Meril Life Sciences Pvt. Ltd. (India)
  • InBios International, Inc. (US)
  • ABACUS Diagnostica Oy (Finland)

Research Coverage:

This report provides a detailed picture of the global infectious disease diagnostics market. It aims at estimating the size and future growth potential of the market across different segments, such as product& service, test of testing, technology,disease type, end user, and region. The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall infectious disease diagnostics market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, and opportunities.

Table of Contents
Product Code: MD 3088

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
    • 1.2.2 MARKETS COVERED
    • 1.2.3 YEARS CONSIDERED FOR THE STUDY
  • 1.3 CURRENCY
  • 1.4 LIMITATIONS
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 RESEARCH APPROACH
    • FIGURE 1 INFECTIOUS DISEASE DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY
    • 2.2.1 SECONDARY DATA
      • 2.2.1.1 Key data from secondary sources
    • 2.2.2 PRIMARY DATA
      • 2.2.2.1 Key data from primary sources
      • 2.2.2.2 Key industry insights
    • FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.3 MARKET SIZE ESTIMATION
    • 2.3.1 BOTTOM-UP APPROACH
    • FIGURE 3 INFECTIOUS DISEASE DIAGNOSTICS MARKET: BOTTOM-UP APPROACH
    • FIGURE 4 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    • 2.3.2 TOP-DOWN APPROACH
    • FIGURE 5 INFECTIOUS DISEASE DIAGNOSTICS MARKET: TOP-DOWN APPROACH
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 6 DATA TRIANGULATION METHODOLOGY
  • 2.5 ASSUMPTIONS FOR THE STUDY
  • 2.6 RISK ASSESSMENT
    • TABLE 1 RISK ASSESSMENT: INFECTIOUS DISEASE DIAGNOSTICS MARKET
  • 2.7 COVID-19 HEALTH ASSESSMENT
  • 2.8 COVID-19 ECONOMIC ASSESSMENT
  • 2.9 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
    • FIGURE 7 CRITERIA IMPACTING THE GLOBAL ECONOMY
    • FIGURE 8 RECOVERY SCENARIO OF THE GLOBAL ECONOMY
  • 2.10 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE INFECTIOUS DISEASE DIAGNOSTICS MARKET

3 EXECUTIVE SUMMARY

    • FIGURE 9 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021 VS. 2026 (USD MILLION)
    • FIGURE 10 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
    • FIGURE 11 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021 VS. 2026 (USD MILLION)
    • FIGURE 12 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
    • FIGURE 13 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)

4 PREMIUM INSIGHTS

  • 4.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET OVERVIEW
    • FIGURE 14 THE RISING ADOPTION OF POC DIAGNOSTICS IS EXPECTED TO SUPPORT MARKET GROWTH DURING THE FORECAST PERIOD
  • 4.2 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021 VS. 2026 (USD MILLION)
    • FIGURE 15 REAGENTS, KITS, AND CONSUMABLES SEGMENT TO COMMAND THE LARGEST SHARE OF THE MARKET, BY PRODUCT & SERVICE, IN 2021
  • 4.3 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
    • FIGURE 16 IMMUNODIAGNOSTICS TO HOLD THE LARGEST SHARE OF THE MARKET DURING THE FORECAST PERIOD
  • 4.4 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021 VS. 2026
    • FIGURE 17 DIAGNOSTIC LABORATORIES DOMINATE THE END-USER MARKET

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 18 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Global prevalence of infectious diseases and onset of COVID-19
      • 5.2.1.2 Rising focus on R&D and funding in infectious disease diagnostics
      • 5.2.1.3 Growing awareness for early disease diagnosis in developing countries
      • 5.2.1.4 Rising technological advancements in infectious disease diagnostics
      • 5.2.1.5 Shift in focus from centralized laboratories to decentralized POC testing
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Unfavorable reimbursement scenario
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growth opportunities in growing economies
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Changing regulatory landscape
      • 5.2.4.2 Operational barriers
    • 5.2.5 COVID-19 IMPACT ANALYSIS
  • 5.3 PRICING ANALYSIS
    • TABLE 2 PRICING ANALYSIS OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS (2021)
  • 5.4 PATENT ANALYSIS
    • 5.4.1 POLYMERASE CHAIN REACTION
    • 5.4.2 IMMUNODIAGNOSTICS
  • 5.5 VALUE CHAIN ANALYSIS
    • FIGURE 19 VALUE CHAIN ANALYSIS OF THE INFECTIOUS DISEASE DIAGNOSTICS MARKET
  • 5.6 SUPPLY CHAIN ANALYSIS
    • FIGURE 20 SUPPLY CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
  • 5.8 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 3 INFECTIOUS DISEASE DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.8.1 THREAT FROM NEW ENTRANTS
    • 5.8.2 THREAT FROM SUBSTITUTES
    • 5.8.3 BARGAINING POWER OF BUYERS
    • 5.8.4 BARGAINING POWER OF SUPPLIERS
    • 5.8.5 COMPETITIVE RIVALRY AMONG EXISTING PLAYERS
  • 5.9 PESTLE ANALYSIS
  • 5.10 REGULATORY LANDSCAPE
    • 5.10.1 NORTH AMERICA
      • 5.10.1.1 US
      • 5.10.1.2 Canada
    • 5.10.2 EUROPE
    • 5.10.3 ASIA PACIFIC
      • 5.10.3.1 China
      • 5.10.3.2 Japan
      • 5.10.3.3 India
    • 5.10.4 LATIN AMERICA
      • 5.10.4.1 Brazil
      • 5.10.4.2 Mexico
    • 5.10.5 MIDDLE EAST
    • 5.10.6 AFRICA
  • 5.11 TRADE ANALYSIS
    • 5.11.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
    • TABLE 4 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2016 - 2020 (USD MILLION)
    • TABLE 5 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2016 - 2020 (TONS)
    • 5.11.2 TRADE ANALYSIS FOR CULTURE MEDIA
    • TABLE 6 IMPORT DATA FOR CULTURE MEDIA, BY COUNTRY, 2016 - 2020 (USD MILLION)
    • TABLE 7 IMPORT DATA FOR CULTURE MEDIA, BY COUNTRY, 2016 - 2020 (TONS)
  • 5.12 TECHNOLOGY ANALYSIS
  • 5.13 YC-YCC SHIFT
    • FIGURE 21 YC-YCC SHIFT FOR THE INFECTIOUS DISEASE DIAGNOSTICS MARKET

6 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE

  • 6.1 INTRODUCTION
    • TABLE 8 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
  • 6.2 REAGENTS, KITS, AND CONSUMABLES
    • 6.2.1 REPEAT PURCHASE OF REAGENTS, KITS, AND CONSUMABLES DRIVES THE MARKET GROWTH
    • TABLE 9 INFECTIOUS DISEASE DIAGNOSTICS REAGENTS, KITS, AND CONSUMABLES MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 6.3 INSTRUMENTS
    • 6.3.1 INCREASING NEED FOR FASTER & ACCURATE TEST RESULTS TO PROPEL THE MARKET GROWTH
    • TABLE 10 KEY PRODUCTS IN THE INSTRUMENTS MARKET
    • TABLE 11 INFECTIOUS DISEASE DIAGNOSTICS INSTRUMENTS MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 6.4 SOFTWARE & SERVICES
    • 6.4.1 NEED TO DELIVER ACCURATE AND TIMELY ANALYSIS OF DIAGNOSTIC TESTS
    • TABLE 12 INFECTIOUS DISEASE DIAGNOSTICS SOFTWARE & SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)

7 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING

  • 7.1 INTRODUCTION
    • TABLE 13 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2019-2026 (USD MILLION)
  • 7.2 LABORATORY TESTING
    • 7.2.1 OUTBREAK OF COVID-19 DRIVES DEMAND FOR LAB TESTS
    • TABLE 14 LABORATORY TESTING MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 7.3 POC TESTING
    • 7.3.1 THE INCREASING ADOPTION OF POC TECHNOLOGIES DRIVES THE GROWTH OF THIS SEGMENT
    • TABLE 15 POC TESTING MARKET, BY REGION, 2019-2026 (USD MILLION)

8 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 8.1 INTRODUCTION
    • TABLE 16 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
  • 8.2 IMMUNODIAGNOSTICS
    • 8.2.1 RISING PREVALENCE OF INFECTIOUS DISEASES AND DEMAND FOR COVID-19 DIAGNOSTICS DRIVE MARKET GROWTH
    • TABLE 17 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY REGION, 2019-2026 (USD MILLION)
  • 8.3 POLYMERASE CHAIN REACTION
    • 8.3.1 THE GROWING USE OF RT-PCR IN COVID-19 TESTS IS A MAJOR GROWTH DRIVER FOR THIS SEGMENT
    • TABLE 18 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR PCR, BY REGION, 2019-2026 (USD MILLION)
  • 8.4 CLINICAL MICROBIOLOGY
    • 8.4.1 GROWING ADOPTION BY RESEARCHERS AND ACADEMIA IS EXPECTED TO DRIVE MARKET GROWTH
    • TABLE 19 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY REGION, 2019-2026 (USD MILLION)
  • 8.5 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
    • 8.5.1 COST-BENEFITS OF INAAT DRIVE DEMAND FOR THE TECHNOLOGY
    • TABLE 20 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2019-2026 (USD MILLION)
  • 8.6 DNA SEQUENCING & NGS
    • 8.6.1 INCREASING FOCUS ON PERSONALIZED MEDICINE IS A GROWTH DRIVER FOR THIS SEGMENT
    • TABLE 21 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY REGION, 2019-2026 (USD MILLION)
  • 8.7 DNA MICROARRAYS
    • 8.7.1 GROWING AWARENESS ABOUT ADVANCED TECHNOLOGIES TO DRIVE MARKET GROWTH
    • TABLE 22 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY REGION, 2019-2026 (USD MILLION)
  • 8.8 OTHER TECHNOLOGIES
    • TABLE 23 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2019-2026 (USD MILLION)

9 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE

  • 9.1 INTRODUCTION
    • TABLE 24 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION)
  • 9.2 COVID-19
    • 9.2.1 HIGH AND GROWING CASE PREVALENCE ENSURES DEMAND FOR COVID-19 DIAGNOSTICS
    • TABLE 25 DISTRIBUTION OF CASES BY COUNTRY
    • TABLE 26 COVID-19 DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 27 COVID-19 DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION TESTS)
    • TABLE 28 COVID-19 DIAGNOSTICS MARKET, BY METHOD, 2019-2026 (USD MILLION)
  • 9.3 HUMAN IMMUNODEFICIENCY VIRUS
    • 9.3.1 THE HIGH PREVALENCE OF HIV WILL DRIVE THE MARKET GROWTH FOR THIS SEGMENT
    • TABLE 29 HIV DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 30 HIV DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION TESTS)
  • 9.4 HOSPITAL-ACQUIRED INFECTIONS
    • 9.4.1 THE RISING BURDEN OF MRSA INFECTIONS IS A KEY FACTOR DRIVING THE MARKET GROWTH FOR THIS SEGMENT
    • TABLE 31 HAI DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 32 HAI DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION TESTS)
  • 9.5 HEPATITIS
    • 9.5.1 THE GLOBAL PREVALENCE OF HEPATITIS IS A KEY FACTOR DRIVING MARKET GROWTH
    • TABLE 33 HEPATITIS DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 34 HEPATITIS DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION TESTS)
    • TABLE 35 HEPATITIS DIAGNOSTICS MARKET, BY METHOD, 2019-2026 (USD MILLION)
  • 9.6 CHLAMYDIA TRACHOMATIS GENITAL INFECTIONS AND GONORRHEA
    • 9.6.1 CT/NG INFECTIONS ARE THE MOST COMMON STDS
    • TABLE 36 CT/NG DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 37 CT/NG DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION TESTS)
  • 9.7 HUMAN PAPILLOMA VIRUS
    • 9.7.1 TECHNOLOGICAL ADVANCEMENTS SUCH AS RAPID HPV DIAGNOSTICS TO DRIVE THE MARKET GROWTH FOR THIS SEGMENT
    • TABLE 38 HPV DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 39 HPV DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION TESTS)
  • 9.8 TUBERCULOSIS
    • 9.8.1 THE INCREASING BURDEN OF TB GLOBALLY TO DRIVE THE MARKET GROWTH OF THIS SEGMENT
    • TABLE 40 TUBERCULOSIS DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 41 TUBERCULOSIS DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION TESTS)
    • TABLE 42 TUBERCULOSIS DIAGNOSTICS MARKET, BY METHOD, 2019-2026 (USD MILLION)
  • 9.9 INFLUENZA
    • 9.9.1 RISING FOCUS ON CONTAINING THE SPREAD OF INFLUENZA
    • TABLE 43 INFLUENZA DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 44 INFLUENZA DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION TESTS)
    • TABLE 45 INFLUENZA DIAGNOSTICS MARKET, BY METHOD, 2019-2026 (USD MILLION)
  • 9.10 OTHER INFECTIOUS DISEASES
    • TABLE 46 OTHER INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)

10 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER

  • 10.1 INTRODUCTION
    • TABLE 47 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 10.2 DIAGNOSTIC LABORATORIES
    • 10.2.1 INCREASING OUTSOURCING TO DIAGNOSTIC LABORATORIES FOR REDUCED COSTS DRIVES MARKET GROWTH
    • TABLE 48 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2019-2026 (USD MILLION)
  • 10.3 HOSPITALS & CLINICS
    • 10.3.1 HOSPITALS & CLINICS SHOW INCREASING ADOPTION RATE OF INFECTIOUS DISEASE DIAGNOSTIC TOOLS
    • TABLE 49 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2019-2026 (USD MILLION)
  • 10.4 ACADEMIC RESEARCH INSTITUTES
    • 10.4.1 FOCUS ON DEVELOPING INNOVATIVE TESTS DRIVES MARKET GROWTH
    • TABLE 50 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2019-2026 (USD MILLION)
  • 10.5 OTHER END USERS
    • TABLE 51 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2019-2026 (USD MILLION)

11 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION

  • 11.1 INTRODUCTION
    • TABLE 52 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 11.2 NORTH AMERICA
    • FIGURE 22 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT
    • TABLE 53 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 54 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 55 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 56 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION)
    • TABLE 57 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 11.2.1 US
      • 11.2.1.1 US dominates the market in North America and globally
    • TABLE 58 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 59 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 60 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION)
    • TABLE 61 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 11.2.2 CANADA
      • 11.2.2.1 Focus on affordable tests drives the market growth
    • TABLE 62 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 63 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 64 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION)
    • TABLE 65 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 11.3 EUROPE
    • TABLE 66 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 67 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 68 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 69 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION)
    • TABLE 70 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 11.3.1 GERMANY
      • 11.3.1.1 Germany holds the largest share of the market in Europe
    • TABLE 71 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 72 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 73 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION)
    • TABLE 74 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 11.3.2 ITALY
      • 11.3.2.1 Adoption of advanced diagnostic technologies to drive market growth in Italy
    • TABLE 75 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 76 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 77 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION)
    • TABLE 78 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 11.3.3 FRANCE
      • 11.3.3.1 Rising R&D expenditure in France
    • TABLE 79 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 80 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 81 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION)
    • TABLE 82 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 11.3.4 SPAIN
      • 11.3.4.1 Healthcare infrastructural improvements indicate favorable prospects for market growth
    • TABLE 83 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 84 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 85 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION)
    • TABLE 86 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 11.3.5 UK
      • 11.3.5.1 The increasing number of accredited diagnostic laboratories propels market growth in the UK
    • TABLE 87 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 88 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 89 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION)
    • TABLE 90 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 11.3.6 REST OF EUROPE
    • TABLE 91 ROE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 92 ROE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 93 ROE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION)
    • TABLE 94 ROE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 11.4 ASIA PACIFIC
    • FIGURE 23 APAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT
    • TABLE 95 APAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 96 APAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 97 APAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 98 APAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION)
    • TABLE 99 APAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 11.4.1 CHINA
      • 11.4.1.1 Growing access to modern healthcare and outbreak of COVID-19
    • TABLE 100 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 101 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 102 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION)
    • TABLE 103 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 11.4.2 JAPAN
      • 11.4.2.1 Universal healthcare reimbursement policy to drive market growth in Japan
    • TABLE 104 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 105 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 106 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION)
    • TABLE 107 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 11.4.3 INDIA
      • 11.4.3.1 Increasing private & public investments in the country's healthcare system will drive market growth
    • TABLE 108 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 109 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 110 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION)
    • TABLE 111 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 11.4.4 REST OF ASIA PACIFIC
    • TABLE 112 ROAPAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 113 ROAPAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 114 ROAPAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION)
    • TABLE 115 ROAPAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 11.5 LATIN AMERICA
    • 11.5.1 RISING DISEASE PREVALENCE AND HEALTHCARE EXPENDITURE HAVE DRAWN FOREIGN PLAYERS TO LATAM MARKETS
    • TABLE 116 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 117 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 118 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION)
    • TABLE 119 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 11.6 MIDDLE EAST & AFRICA
    • 11.6.1 RISING ACCESS TO ADVANCED TECHNOLOGIES AND GROWING INVESTMENTS WILL SUPPORT MARKET GROWTH
    • TABLE 120 MEA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 121 MEA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 122 MEA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION)
    • TABLE 123 MEA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)

12 COMPETITIVE LANDSCAPE

  • 12.1 OVERVIEW
    • FIGURE 24 KEY STRATEGIES IN THE INFECTIOUS DISEASE DIAGNOSTICS MARKET (2018-2021)
  • 12.2 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
    • FIGURE 25 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS IN THE INFECTIOUS DISEASE DIAGNOSTICS MARKET
  • 12.3 MARKET SHARE ANALYSIS
    • FIGURE 26 INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2020)
    • 12.3.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET RANKING, BY DISEASE TYPE
      • 12.3.1.1 Hepatitis
    • TABLE 124 GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY KEY PLAYER, 2020
      • 12.3.1.2 HIV
    • TABLE 125 GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY KEY PLAYER, 2020
      • 12.3.1.3 HPV
    • TABLE 126 GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY KEY PLAYER, 2020
      • 12.3.1.4 Influenza
    • TABLE 127 GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY KEY PLAYER, 2020
      • 12.3.1.5 COVID-19
    • TABLE 128 GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR COVID-19, BY KEY PLAYER, 2020
  • 12.4 COMPANY EVALUATION QUADRANT
    • 12.4.1 STARS
    • 12.4.2 EMERGING LEADERS
    • 12.4.3 PERVASIVE PLAYERS
    • 12.4.4 PARTICIPANTS
    • FIGURE 27 INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPANY EVALUATION QUADRANT, 2020
  • 12.5 COMPANY EVALUATION QUADRANT FOR START-UPS/SMES (2020)
    • 12.5.1 PROGRESSIVE COMPANIES
    • 12.5.2 STARTING BLOCKS
    • 12.5.3 RESPONSIVE COMPANIES
    • 12.5.4 DYNAMIC COMPANIES
    • FIGURE 28 INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES (2020)
  • 12.6 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS OF TOP PLAYERS
    • FIGURE 29 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN THE INFECTIOUS DISEASE DIAGNOSTICS MARKET
  • 12.7 COMPETITIVE SCENARIO
    • 12.7.1 MARKET EVALUATION MATRIX, 2018-2020
    • 12.7.2 INFECTIOUS DISEASE DIAGNOSTICS: PRODUCT LAUNCHES & APPROVALS
    • TABLE 129 KEY PRODUCT LAUNCHES & APPROVALS
    • 12.7.3 INFECTIOUS DISEASE DIAGNOSTICS: DEALS
    • TABLE 130 KEY DEALS
    • 12.7.4 INFECTIOUS DISEASE DIAGNOSTICS: OTHER DEVELOPMENTS
    • TABLE 131 OTHER KEY DEVELOPMENTS

13 COMPANY PROFILES

  • 13.1 KEY PLAYERS
  • (Business Overview, Products Offered, Recent Developments, SWOT Analysis, right to win)**
    • 13.1.1 ABBOTT LABORATORIES
    • TABLE 132 ABBOTT LABORATORIES: BUSINESS OVERVIEW
    • FIGURE 30 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020)
    • 13.1.2 F. HOFFMANN-LA ROCHE
    • TABLE 133 F. HOFFMANN-LA ROCHE: BUSINESS OVERVIEW
    • FIGURE 31 F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT (2020)
    • 13.1.3 BIOMERIEUX SA
    • TABLE 134 BIOMERIEUX SA: BUSINESS OVERVIEW
    • FIGURE 32 BIOMERIEUX SA: COMPANY SNAPSHOT (2020)
    • 13.1.4 THERMO FISHER SCIENTIFIC
    • TABLE 135 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
    • FIGURE 33 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2020)
    • 13.1.5 DANAHER CORPORATION
    • TABLE 136 DANAHER CORPORATION: BUSINESS OVERVIEW
    • FIGURE 34 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)
    • 13.1.6 QUIDEL CORPORATION
    • TABLE 137 QUIDEL CORPORATION: BUSINESS OVERVIEW
    • FIGURE 35 QUIDEL CORPORATION: COMPANY SNAPSHOT (2020)
    • 13.1.7 HOLOGIC
    • TABLE 138 HOLOGIC: BUSINESS OVERVIEW
    • FIGURE 36 HOLOGIC: COMPANY SNAPSHOT (2020)
    • 13.1.8 PERKINELMER
    • TABLE 139 PERKINELMER: BUSINESS OVERVIEW
    • FIGURE 37 PERKINELMER: COMPANY SNAPSHOT (2020)
    • 13.1.9 BECTON, DICKINSON AND COMPANY
    • TABLE 140 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
    • FIGURE 38 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)
    • 13.1.10 SIEMENS HEALTHINEERS AG
    • TABLE 141 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW
    • FIGURE 39 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2020)
    • 13.1.11 DIASORIN S.P.A
    • TABLE 142 DIASORIN S.P.A: BUSINESS OVERVIEW
    • FIGURE 40 DIASORIN S.P.A: COMPANY SNAPSHOT (2020)
    • 13.1.12 BIO-RAD LABORATORIES
    • TABLE 143 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
    • FIGURE 41 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2020)
    • 13.1.13 QIAGEN
    • TABLE 144 QIAGEN: BUSINESS OVERVIEW
    • FIGURE 42 QIAGEN N.V.: COMPANY SNAPSHOT (2020)
    • 13.1.14 GRIFOLS S.A.
    • TABLE 145 GRIFOLS S.A.: BUSINESS OVERVIEW
    • FIGURE 43 GRIFOLS S.A.: COMPANY SNAPSHOT (2020)
    • 13.1.15 ORTHO CLINICAL DIAGNOSTICS
    • TABLE 146 ORTHO CLINICAL DIAGNOSTICS: BUSINESS OVERVIEW
    • FIGURE 44 ORTHO CLINICAL DIAGNOSTICS: COMPANY SNAPSHOT (2020)
    • 13.1.16 SYSMEX CORPORATION
    • TABLE 147 SYSMEX CORPORATION: BUSINESS OVERVIEW
    • FIGURE 45 SYSMEX CORPORATION: COMPANY SNAPSHOT (2020)
  • 13.2 OTHER PLAYERS
    • 13.2.1 LUMINEX CORPORATION
    • 13.2.2 MERIDIAN BIOSCIENCE
    • 13.2.3 TRINITY BIOTECH
    • 13.2.4 CHEMBIO DIAGNOSTIC SYSTEMS
    • 13.2.5 ORASURE TECHNOLOGIES
    • 13.2.6 SEEGENE
    • 13.2.7 CO-DIAGNOSTICS
    • 13.2.8 GENETIC SIGNATURES
    • 13.2.9 EPITOPE DIAGNOSTICS
    • 13.2.10 TRIVITRON HEALTHCARE
    • 13.2.11 ELITECHGROUP
    • 13.2.12 MERIL LIFESCIENCES PVT. LTD.
    • 13.2.13 INBIOS INTERNATIONAL
    • 13.2.14 ABACUS DIAGNOSTICA OY
  • *Details on Business Overview, Products Offered, Recent Developments, SWOT Analysis, right to win might not be captured in case of unlisted companies.

14 APPENDIX

  • 14.1 INSIGHTS FROM INDUSTRY EXPERTS
  • 14.2 DISCUSSION GUIDE
  • 14.3 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.4 AVAILABLE CUSTOMIZATIONS
  • 14.5 RELATED REPORTS
  • 14.6 AUTHOR DETAILS
Back to Top